首頁 > 市場調查報告書 > 製藥

孤兒藥

市場調查報告書

商品編碼

1465570

龐貝氏症治療市場規模- 按治療類型（ERT、支持性護理）、按疾病類型（嬰兒、青少年）、按治療類型（單一療法、聯合療法）、按最終用戶（醫院、輸液護理）和預測， 2024 年 - 2032

Pompe Disease Treatment Market Size - By Treatment Type (ERT, Supportive Care), By Disease Type (Infantile, Juvenile), By Therapy Type (Monotherapy, Combination Therapy), By End-user (Hospitals, Infusion Care) & Forecast, 2024 - 2032

出版日期: 2024年02月28日 | 出版商:

Global Market Insights Inc. | 英文 170 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在治療計畫投資和資金不斷增加的推動下，2024 年至 2032 年間，全球龐貝氏症治療市場規模將達到 4.4% 的複合年成長率。隨著人們對龐貝氏症的認知不斷提高，人們對它對受影響個體的影響也有了更深入的了解，人們齊心協力發展有效的治療方法。例如，2023 年 11 月，在 B 輪融資中，臨床階段生物技術公司 Aro Biotherapeutics 獲得了 4,150 萬美元，以進一步推進其針對龐貝氏症的主要候選藥物 ABX1100 的開發。

製藥公司、研究機構和政府組織正在將資源投入研發項目，旨在發現龐貝氏症的新療法和改進現有療法。此外，患者權益團體和公私合作夥伴關係等措施進一步推動了治療開發的投資。這項集體努力有助於擴大龐貝氏症患者可用的治療選擇，同時強調合作方法在解決罕見疾病和改善患者預後方面的重要性。

整個龐貝氏症治療產業根據治療類型、疾病類型、治療類型、最終用途和地區進行分類。

到 2032 年，支持性護理領域將出現顯著成長。這包括呼吸支持、物理治療和營養管理等干涉措施。隨著醫療保健提供者優先考慮患者護理的整體方法，龐貝病治療市場對支持性療法的需求持續成長，以確保受影響個體的全面管理和改善結果。

從 2023 年到 2032 年，嬰兒龐貝氏症治療市場將呈現顯著成長。酵素替代療法 (ERT) 和支持性護理等療法在治療嬰兒龐貝氏症方面發揮著至關重要的作用。由於早期診斷和介入對嬰兒至關重要，因此對滿足這一弱勢群體的特定需求的有效治療的需求不斷增加，從而推動了龐貝氏症治療市場的創新和進步。

歐洲龐貝氏症治療市場將在2024年至2032年呈現出值得稱讚的複合年成長率。早期診斷和有效管理。歐洲國家優先考慮獲得創新療法，包括酵素替代療法（ERT）和支持性護理，以改善患者的治療效果。

隨著醫療保健提供者和政策制定者合作滿足龐貝氏症患者的需求，歐洲對綜合治療方案的需求繼續推動市場成長並促進醫療保健服務的進步。例如，2024 年 2 月，法國生物製藥公司賽諾菲報告稱，其酵素替代療法 avalglucosidase alfa 在不同龐貝病患者群體中取得了令人鼓舞的結果。

產業生態系統分析
產業影響力
- 成長動力
  - 龐貝氏症發生率不斷上升
  - 擴大研發力度
  - 不斷增加的監管支持
  - 越來越重視早期診斷的進步
  - 優惠報銷政策
- 產業陷阱與挑戰
  - 治療選擇有限
  - 治療費用高
成長潛力分析
管道評估
報銷場景
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀錶板

第 5 章：市場估計與預測：按治療類型，2018 - 2032 年

主要趨勢
酵素替代療法（ERT）
支持性護理

第 6 章：市場估計與預測：按疾病類型，2018 - 2032

主要趨勢
嬰兒型
少年

第 7 章：市場估計與預測：按治療方式，2018 - 2032 年

主要趨勢
單一療法
合併治療

第 8 章：市場估計與預測：按最終用戶分類，2018 年 - 2032 年

主要趨勢
醫院
點滴中心
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

Abeona Therapeutics Inc.
Amicus Therapeutics, Inc.
Aro Biotherapeutics Company
Audentes Therapeutics (Astellas Pharma Inc.)
Bayer AG
F. Hoffmann-La Roche Ltd.
Genethon
Maze Therapeutics
M6P Therapeutics
Oxyrane
Sanofi
Valerion Therapeutics

簡介目錄

Product Code: 8315

Global Pompe Disease Treatment Market size will witness a 4.4% CAGR between 2024 and 2032, propelled by escalating investments and funding in treatment initiatives. As awareness about Pompe disease grows and its impact on affected individuals becomes better understood, there has been a concerted effort to develop effective therapies. For instance, in November 2023, in a Series B financing round, clinical-stage biotechnology firm Aro Biotherapeutics secured $41.5 million to further progress the development of its primary candidate, ABX1100, targeting Pompe disease.

Pharmaceutical companies, research institutions, and government organizations are channeling resources into research and development projects aimed at discovering novel treatments and improving existing therapies for Pompe disease. Additionally, initiatives such as patient advocacy groups and public-private partnerships further drive investments in treatment development. This collective effort helps expand the treatment options available to Pompe disease patients while underscoring the importance of collaborative approaches in addressing rare diseases and improving patient outcomes.

The overall Pompe Disease Treatment Industry is classified based on the treatment type, disease type, therapy type, end-use, and region.

The supportive care segment will register a significant growth rate by 2032. As Pompe disease affects multiple organs and systems in the body, patients often require comprehensive supportive care to manage symptoms and improve their quality of life. This includes interventions such as respiratory support, physical therapy, and nutritional management. As healthcare providers prioritize holistic approaches to patient care, the demand for supportive therapies in the Pompe Disease Treatment Market continues to grow, ensuring comprehensive management and improved outcomes for affected individuals.

The Pompe disease treatment market from infantile segment will exhibit significant growth from 2023 to 2032. Infantile-onset Pompe disease, a severe form of the disorder, requires prompt and comprehensive treatment to mitigate symptoms and improve outcomes. Therapies such as enzyme replacement therapy (ERT) and supportive care play a crucial role in managing infantile Pompe disease. As early diagnosis and intervention are pivotal for infants, there is a heightened demand for effective treatments tailored to address the specific needs of this vulnerable population, driving innovation and advancements in the Pompe Disease Treatment Market.

Europe Pompe disease treatment market will showcase a commendable CAGR from 2024 to 2032. With advanced healthcare systems and increasing awareness about rare diseases, there's a growing emphasis on early diagnosis and effective management of Pompe disease. European countries prioritize access to innovative therapies, including enzyme replacement therapy (ERT) and supportive care, to improve patient outcomes.

As healthcare providers and policymakers collaborate to address the needs of Pompe disease patients, the demand for comprehensive treatment options in Europe continues to drive market growth and foster advancements in healthcare delivery. For instance, in February 2024, Sanofi, the French biopharmaceutical company, reported encouraging outcomes for its enzyme replacement therapy, avalglucosidase alfa, in diverse Pompe disease patient cohorts.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data validation
1.4 Forecast parameters
1.5 Data sources
- 1.5.1 Primary
- 1.5.2 Secondary
  - 1.5.2.1 Paid sources
  - 1.5.2.2 Public sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing incidence of pompe disease
  - 3.2.1.2 Expanding R&D efforts
  - 3.2.1.3 Growing regulatory support
  - 3.2.1.4 Increasing emphasis on early diagnosis advancement
  - 3.2.1.5 Favorable reimbursement policies
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Limited treatment options
  - 3.2.2.2 High treatment costs
3.3 Growth potential analysis
3.4 Pipeline assessment
3.5 Reimbursement scenario
3.6 Regulatory landscape
3.7 Porter's analysis
- 3.7.1 Supplier power
- 3.7.2 Buyer power
- 3.7.3 Threat of new entrants
- 3.7.4 Threat of substitutes
- 3.7.5 Industry rivalry
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Enzyme replacement therapy (ERT)
5.3 Supportive care

Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Infantile
6.3 Juvenile

Chapter 7 Market Estimates and Forecast, By Therapy, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Monotherapy
7.3 Combination therapy

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Infusion centers
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa